Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT06923761
NCT06923761RecruitingPhase 1

A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination With Anticancer Treatments in Patients With Solid Malignancies

Grey Wolf Therapeutics30 sites in 4 countries300 target enrollmentStarted: May 21, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Interventions

Trial Snapshot

Phase
Phase 1
Status
Recruiting
Sponsor
Enrollment
300
Locations
30
Primary Endpoint
Incidence of Dose limiting toxicities (DLT)
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This is a Phase I/II, open-label, first-in human study of GRWD5769 alone, and in combination with another anti-cancer agent in advanced solid cancers.

Detailed Description

GRWD5769 is as a potential new treatment for advanced or metastatic solid malignancies. GRWD5769 works by stopping an enzyme in the body, called endoplasmic reticulum aminopeptidase 1 (ERAP1), from working. ERAP1 is part of how the body recognizes the presence of a cancer tumour and helps trigger the immune system to fight the cancer. However, in patients with cancer, the immune system cells can become exhausted and no longer work effectively. By blocking ERAP1 it makes the tumour look different to the immune system and so the immune system starts fighting the cancer again. GRWD5769 has the potential of producing clinically meaningful improvements in monotherapy and in combination with therapy like cemiplimab (Libtayo®) by enhancing the antitumour immune response.

Who can participate? Patients with advanced or metastatic solid malignancy aged 18 years or older.

What does the study involve? This study consists of Module 1 (Parts A to D), which will look at the effects of GRWD5769 when given alone and Module 2 (Parts A to D) which will look at the effects of GRWD5769 when given in combination with another anticancer drug called Libtayo® (cemiplimab).

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Sequential
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Provision of written informed consent.
  • •Male or female, ≥ 18 years of age.
  • •An ECOG performance status of 0 or
  • •Willing to permit access to stored historical tumour tissue and prior tumour radiological assessments and tumour biomarker data (if available).
  • •Able to take oral medications and be willing to record daily adherence to the study drug.
  • •Female participants must be of non-child-bearing potential, or, if of childbearing potential must have a negative pregnancy test (as required by protocol), must use a highly effective method of contraception combined with a condom and not donate ova (for the protocol specified period of time).
  • •Male participants must use a condom and their female participant must also use a highly effective method of contraception (for the protocol specified period of time), if engaging in sexual intercourse with a female partner who could become pregnant and not donate sperm.
  • •Estimated life expectancy of at least 3 months, in the opinion of the PI.
  • •Willing and able to comply with all scheduled visits, treatment plans, laboratory tests, and other study procedures.
  • •Participant has measurable disease per RECIST 1.1/iRECIST
  • •Participant has cytologically or histologically confirmed locally advanced or metastatic solid malignancy for which no further standard of care (SoC) therapy is available (or no SoC therapy exists), or who have been offered and declined SoC therapy, or are intolerant of SoC therapy.
  • •Module 1 (Part B) and Module 2 (Part B) Only
  • •Participant has at least one tumour lesion amenable to serial biopsies and is willing to provide consent for biopsies and has measurable disease per RECIST 1.1/iRECIST, excluding the lesion(s) identified for biopsy.
  • •Module 2 (Part C and Part D)
  • •Cohort 1 (Cervical)
  • •Participants with histologically confirmed persistent, recurrent or metastatic cervical cancer who are not amenable to curative therapy.
  • •Participants should have received at least 3 months first line anti-PD(L)-1 therapy (± bevacizumab, chemotherapy, ADC or other immunotherapy e.g. anti-CTLA-4) and this should have included at least a 10-week period without progression.
  • •Participants may enrol in the study immediately following progression on the first line CPI or may have received 1 further line of systemic cancer therapy after progression on CPI.
  • •Cohort 2 (Hepatocellular Carcinoma)
  • •Participants with histologically confirmed hepatocellular carcinoma who are not amenable to curative therapy and ineligible for loco-regional therapy.
  • •Participants should have received at least 3 months first line anti-PD(L)-1 containing therapy and this should have included at least a 10-week period without progression per Investigator assessment.
  • •Participants may enrol in the study immediately following progression on the first line CPI or may have received 1 further line of systemic cancer therapy after progression on CPI.
  • •Participant has Child-Pugh score class A liver function.
  • •Cohort 3 (Moderate to High TMB)
  • •Participants with cytologically or histologically confirmed advanced, recurrent or metastatic disease, which is not amenable to curative therapy, in up to 5 types of solid tumour with moderate to high median TMB (NSCLC, urothelial, SCCHN, gastric/gastro-oesophageal adenocarcinoma, oesophageal SCC).
  • •Participants should have received at least ≥ 3 months first line anti-PD(L)-1 (± chemotherapy, ADC, pemetrexed or other immunotherapy e.g. anti-CTLA-4) and this should have included at least a 10-week period without progression.
  • •Participants may enrol in the study immediately following progression on the first line CPI or may have received 1 further line of systemic cancer therapy after progression on CPI.
  • •Module 2 Part D only (pMMR/MSS-CRC)
  • •Participants with histologically confirmed unresectable pMMR/MSS-CRC, without current or prior liver metastases
  • •Participants should have received at least one line of therapy in the advanced/metastatic setting and should have received therapies according to local standard practice, unless ineligible or intolerant to the treatment
  • •Participants may not have received more than 2 lines of cytotoxic chemotherapy

Exclusion Criteria

  • •Prior therapy with an ERAP1 inhibitor.
  • •Any other malignancy within the past 3 years, with the exception of cervical intraepithelial neoplasia and nonmelanoma skin cancer.
  • •Any unresolved toxicity (except alopecia) from prior therapy of ≥ CTCAE Grade
  • •Participants with Grade 2 toxicity that is not clinically significant (e.g., alopecia, vitiligo), or that is deemed stable or irreversible (e.g., peripheral neuropathy) can be enrolled.
  • •Active or documented history of autoimmune disease (within 2 years) requiring systemic immunosuppressive therapy, or participant is immunocompromised for any other reason (as determined by the Investigator).
  • •Spinal cord compression or brain metastases, unless asymptomatic, stable, and not requiring steroids for at least 4 weeks (if stable and requiring no intervention, the participant can be enrolled in the study).
  • •Uncontrolled seizures.
  • •Active infection requiring therapy within 14 days prior to the day of first dose of IMP.
  • •Severe or uncontrolled medical condition (e.g., severe chronic obstructive pulmonary disease, severe Parkinson's disease, active inflammatory bowel disease) or psychiatric condition.
  • •Active bleeding diatheses.
  • •Participant has received an organ transplant.
  • •Known active hepatitis B, hepatitis C, or human immunodeficiency virus infection (HIV).
  • •Participant is breastfeeding or pregnant.
  • •Receipt of licenced or unlicenced cytotoxic, noncytotoxic or small molecule treatment for the malignancy within 28 days or 5 half-lives, whichever is shorter prior to the day of first dose of IMP.
  • •Receipt of oral corticosteroids (at a dose > 10 mg prednisone/day or equivalent) within 14 days (except for subjects receiving corticosteroids for adrenal insufficiency).
  • •Receipt of St John's Wort or of another concomitant medication, herbal supplement, or food that is a strong inhibitor or inducer of CYP3A4 enzymes within 14 days.
  • •Receipt of a blood transfusion (blood or blood products) within 7 days.
  • •Impaired hepatic or renal function.
  • •Liver function deteriorating in a manner that would likely make the participant ineligible per protocol specified requirements.
  • •Other evidence of impaired hepatic synthesis function.
  • •Inadequate bone marrow reserve or organ function.
  • •Any prior history of persistent (> 4 weeks) severe pancytopenia due to previous therapy rather than to disease (ANC < 0.5 × 10^9/L or platelets < 50 x 10^9/L).
  • •Cardiac dysfunction or other clinically significant cardiac pathology likely to impair the participants ability to participate in the study.
  • •Mean QTcF > 450 ms for males or > 470 ms for females.
  • •Any clinically important abnormalities in rhythm, conduction, or morphology on resting ECG. Controlled atrial fibrillation is permitted.
  • •Any factor that in the Investigator's opinion increases the risk of QTc prolongation or arrythmic events.
  • •In the opinion of the Investigator, unlikely to comply with study procedures, restrictions, or requirements.
  • •A history of haemolytic anaemia or marrow aplasia.
  • •Has received a live-virus vaccination within 28 days. Note: seasonal flu or COVID vaccines that do not contain live virus are permitted.
  • •History of Grade 3 or 4 pneumonitis or interstitial lung disease within the last 5 years, or other clinically significant pulmonary pathology likely to impair ability to participate in the study.
  • •Module 2 all Parts and Module 1A Crossover Participants Only
  • •Has discontinued a prior checkpoint inhibitor due to toxicity.
  • •Hypersensitivity to cemiplimab or any of its excipients, or contraindicated to cemiplimab per approved local labelling.
  • •Has experienced ≥ Grade 2 immune-mediated AE on this study (applies to crossover participants only).
  • •Module 2 Part D only - pMMR/MSS CRC dose optimisation cohort
  • •Participants with unresectable pMMR/MSS CRC may not have purely peritoneal disease
  • •Participants with unresectable pMMR/MSS CRC may not have had prior CPI / immunotherapy

Arms & Interventions

Module 1 (GRWD5769 on its own as monotherapy)

Experimental

Intervention: Module 1 (GRWD5769 on its own as monotherapy) (Drug)

Module 2 (GRWD5769 in combination with cemiplimab, administered IV)

Experimental

Intervention: Module 2 (GRWD5769 in combination with cemiplimab, administered IV) (Drug)

Outcomes

Primary Outcomes

Incidence of Dose limiting toxicities (DLT)

Time Frame: End of cycle 1 (each cycle is 21 days)

Incidence of Dose limiting toxicities (DLT) during the DLT period which commences Cycle 0 Day 1 and continues to 21 days after Cycle 1 Day 1

Number of treatment emergent and treatment related AEs

Time Frame: From first dose to 30 days after last dose of GRWD5769 for Module 1 and 90 days after last dose of cemiplimab for Module 2 Parts A-C.

Incidence of treatment emergent and treatment related AEs assessed from start of study drug to 30 days post last dose of GRWD5769 (Module 1) or to 90 days post last dose of cemiplimab (Module 2 Parts A-C).

Comparative efficacy (for Module 2D only)

Time Frame: From baseline to week 16

Comparative efficacy will be evaluated or assessed using the change in dimension over time of RECIST Target Lesions from baseline and on-study scans recorded at weeks 8 and 16

Secondary Outcomes

  • Time To Response (TTR)(Up to approximately 1 year)
  • GRWD5769 Plasma PK Trough concentration(Up to approximately 1 year)
  • Objective response rate (ORR)(Up to approximately 1 year)
  • GRWD5769 Plasma PK Oral Clearance(Up to approximately 1 year)
  • GRWD5769 Plasma PK Vss/F(Up to approximately 1 year)
  • Disease Control Rate (DCR)(Up to approximately 1 year)
  • Stable Disease Rate (SDR)(Up to approximately 1 year)
  • Progression - Free Survival (PFS)(Up to approximately 1 year)
  • Disease specific tumour markers(Up to approximately 1 year)
  • GRWD5769 Plasma PK Cmax(Up to approximately 1 year)
  • GRWD5769 Plasma PK Tmax(Up to approximately 1 year)
  • GRWD5769 Plasma PK AUC0-t(Up to approximately 1 year)
  • GRWD5769 Plasma PK Half-life(Up to approximately 1 year)
  • Duration Of Response (DOR)(Up to approximately 1 year)
  • Number of treatment emergent and treatment related AEs (for Module 2D only)(90 days after last dose of cemiplimab)
  • Incidence of Dose limiting toxicities (DLT) (for Module 2D only)(End of cycle 1 (each cycle is 21 days))
  • Overall Survival(Up to approximately 1 year)

Investigators

Sponsor
Grey Wolf Therapeutics
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (30)

Loading locations...

Similar Trials

Terminated
Phase 1
A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid TumorsCancer
NCT02317419Hoffmann-La Roche15
Terminated
Phase 1
First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaAcute Myeloid Leukemia
NCT05817058Affimed GmbH30
Active, not recruiting
Phase 1
Phase I/II study of ANV600 single agent or in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1)Advanced solid tumoursMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104
CTIS2023-509633-39-00Anaveon AG240
Recruiting
Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid TumorHER2-Positive Solid Tumor
NCT05523947Yuhan Corporation147
Active, not recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular CarcinomaHepatocellular Carcinoma
NCT05595473Rznomics, Inc.42